Meeting
2023 ASCO Annual Meeting
Olaparib (O) + ceralasertib (C) in patients (pts) with metastatic triple-negative breast cancer (mTNBC): Translational analysis of the VIOLETTE trial.
Authors
Natalia Lukashchuk
AstraZeneca, Cambridge, United Kingdom
Natalia Lukashchuk , Kevin Punie , Zbigniew Nowecki , Seock-Ah Im , Anne C. Armstrong , William Jacot , Jee Hyun Kim , Marc A. Webster , Judith Balmaña , Suzette Delaloge , Ed Casson , Bienvenu Loembe , Emma Dean , Joshua Armenia , Andrew NJ Tutt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT03330847
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1087)
DOI
10.1200/JCO.2023.41.16_suppl.1087
Abstract #
1087
Poster Bd #
308
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.
First Author: Elias Chandran
Poster
2023 ASCO Annual Meeting
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
First Author: June Evelyn Jeon
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2022 ASCO Genitourinary Cancers Symposium
Frequencies of actionable alterations found by somatic tumor sequencing in veterans with metastatic prostate cancer.
First Author: Nicholas George Nickols